XML 21 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues:    
Total revenues $ 6,780,000 $ 8,034,000
Operating expenses (income):    
Cost of product revenues 8,708,000 5,199,000
Research and development 3,889,000 7,960,000
Gain on sale of Verdeca   (8,814,000)
Loss on sale of Arcadia Spain 497,000  
Impairment of intangible asset 3,302,000 0
Impairment of goodwill 1,648,000 0
Change in fair value of contingent consideration (210,000)  
Impairment of property and equipment, net 1,534,000 0
Selling, general and administrative 22,938,000 16,467,000
Total operating expenses 42,306,000 20,812,000
Loss from operations (35,526,000) (12,778,000)
Interest expense (20,000) (47,000)
Other income, net 10,114,000 740,000
Change in fair value of common stock warrant liabilities 8,946,000 6,570,000
Loss on extinguishment of warrant liability   (635,000)
Gain on extinguishment of PPP loan 1,123,000  
Offering costs (769,000)  
Net loss before income taxes (16,132,000) (6,150,000)
Income tax (provision) benefit (2,000) 124,000
Net loss (16,134,000) (6,026,000)
Net loss attributable to non-controlling interest (1,474,000) (1,371,000)
Net loss attributable to common stockholders $ (14,660,000) $ (4,655,000)
Net loss per share attributable to common stockholders:    
Basic and diluted $ (0.69) $ (0.47)
Weighted-average number of shares used in per share calculations:    
Basic and diluted 21,280,620 9,959,018
Other comprehensive loss, net of tax    
Unrealized losses on investment securities   $ (1,000)
Other comprehensive loss   (1,000)
Comprehensive loss attributable to common stockholders $ (14,660,000) (4,656,000)
Product    
Revenues:    
Total revenues 6,587,000 1,044,000
License    
Revenues:    
Total revenues 17,000 6,801,000
Royalty    
Revenues:    
Total revenues $ 176,000 83,000
Contract Research And Government Grants    
Revenues:    
Total revenues   $ 106,000